Results

Total Results: 108 records

Showing results for "discharge".
Users also searched for: discharge planning

81. Chemo and Couns/2nd instal (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-hnLT26c2NHs6thK9yznPF
    July 01, 2002 - given) and Chemoprevention of Breast Cancer 38 “quite a bit” or “extremely” bothersome vaginal discharge

82. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction-2002
    May 06, 2002 - placebo group, statistical significance not given) and "quite a bit" or "extremely" bothersome vaginal discharge

83. Evidence Summary: High Body Mass Index in Children and Adolescents: Interventions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/obesity-in-children-and-adolescents-screening
    June 18, 2024 - = 579 Gastrointestinal adverse effects were more common with orlistat use, including flatus with discharge

84. 3W8Wr9Wwayaqujwmjo Bl- (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/3w8Wr9wwAyAqUJWmJo_bL-
    February 01, 2014 - The most common adverse effects were vasomotor symp- toms and vaginal discharge, itching, or dryness

85. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
    September 15, 2013 - The most commonly reported adverse effects in these trials were vasomotor symptoms and vaginal discharge

86. Recommendation: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing
    August 20, 2019 - placebo or raloxifene. 79 , 90 The most common adverse effects were vasomotor symptoms and vaginal discharge

87. Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/e9f8a_uGMXxSbBUxpRPkrc
    June 18, 2024 - n = 579 Gastrointestinal adverse effects were more common with orlistat use, including flatus with discharge

88. Zvvry6Wa4Sgj-Ejb3Brcvy (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
    November 01, 2013 - The most commonly reported adverse effects in these trials were vasomotor symptoms and vaginal discharge

89. JAMA (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/pACFPdCoN8fVoddBs-_CLE
    November 12, 2019 - with placebo or raloxifene.79,90 The most common adverse effects were vasomotor symptoms and vaginal discharge

90. Archived: Evidence Summary: Falls Prevention in Community-Dwelling Older Adults: Interventions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/falls-prevention-in-older-adults-interventions-2018
    April 17, 2018 - Share to Facebook Share to X Share to WhatsApp Share to Email Print archived Evidence Summary Falls Prevention in Community-Dwelling Older Adults: Interventions April 17, 2018 Recommendations made by the USPSTF are independent of the U.S.…

91. Archived: Evidence Summary: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary17/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing-2013
    December 15, 2013 - The most common adverse effects were vasomotor symptoms and vaginal discharge, itching, or dryness for

92. Final Evidence Summary: Hepatitis C Virus Infection in Adolescents and Adults: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/hepatitis-c-screening
    March 02, 2020 - Share to Facebook Share to X Share to WhatsApp Share to Email Print Final Evidence Summary Hepatitis C Virus Infection in Adolescents and Adults: Screening March 02, 2020 Recommendations made by the USPSTF are independent of the U.S. govern…

93. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary27/breast-cancer-medications-for-risk-reduction-2013
    April 15, 2013 - The most common side effects were vasomotor symptoms 11 , 24 , 28 , 31  and vaginal discharge, itching

94. Archived: Evidence Summary: Obesity in Children and Adolescents: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/obesity-in-children-and-adolescents-screening-june-2017
    June 20, 2017 - Flatus with discharge was reported by 20% to 43% of those taking orlistat and 3% to 11% of those receiving

95. Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/MWRHULpw6y_5Uk_KXTyvp8
    January 10, 2017 - It identified cases, largely from hospital discharge records; randomly selected controls; and identified

96. Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review of the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/7ZSKduUYHWKe7q_tTY9xbF
    April 01, 2013 - The most common side effects were vasomotor symp- toms (11, 24, 28, 31) and vaginal discharge, itching

97. Z8Avschjezubsjtdsx424H (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/z8AVsCHJEZUBSJtdSx424H
    May 23, 2019 - brief motivational interviewing, skills-based counseling, or usual care on alcohol consumption after discharge

98. Archived: Final Evidence Summary: Obesity in Children and Adolescents: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary39/obesity-in-children-and-adolescents-screening-2010
    January 15, 2010 - and 20% to 30% reported oily spotting, oily evacuation, abdominal pain, fecal urgency, or flatus with discharge

99. Effectiveness of Weight Management Interventions in Children: A Targeted Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/b5LjDb3-UoPV8LEWavJWB8
    February 01, 2010 - 20% to 30% reported oily spotting, oily evacuation, abdominal pain, fecal urgency, or fla- tus with discharge

100. Archived: Evidence Summary: Breast and Ovarian Cancer: BRCA Genetic Testing, September 2005 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-and-ovarian-cancer-brca-testing-screening-2005
     September 15, 2005 - ). 133 Trials reported significantly increased cataracts; 134 hot flashes; 133-135 , 144 vaginal discharge